Lakefront Biotherapeutics | GLPG - Cash And Equivalent


Lakefront Biotherapeutics reported EUR66.8M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
argenx SE USD 4.3B 808.71M Mar/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
Genmab DKK 1.72B 46M Dec/2025
Gilead Sciences USD 7.63B 64M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GRIFOLS EUR 513M 189M Jun/2026
Hikma Pharmaceutical USD 217M 19M Dec/2025
Incyte USD 3.98B 33.45M Jun/2026
Merck EUR 2.33B 77M Dec/2025
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Novartis USD 7.62B 739M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
UCB EUR 1.57B 1.14B Dec/2024
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026